Elana B.V.

Elana B.V. specializes in vascular-grafting anastomosis systems, which are designed to facilitate precise and secure connections between blood vessels. These systems are primarily used in surgical procedures like bypass surgeries or vascular repairs, where maintaining proper blood flow is critical. The company’s focus is on devices that help surgeons create reliable anastomoses, reducing complications during complex vascular interventions.

Elana B.V. is based in the United States, which means its devices are subject to U.S. regulatory requirements. Since the company’s products are listed in the FDA’s Unique Device Identification (UDI) system, they must comply with FDA guidelines for medical device registration and labeling. The UDI system ensures traceability and transparency in the supply chain, which is essential for post-market surveillance and patient safety.

Elana B.V.’s devices fall under the category of unclassified medical devices in the U.S. regulatory framework. This classification means they do not fit neatly into the standard risk-based classes (I, II, or III) established by the FDA, likely due to their unique design or intended use. While unclassified devices still require compliance with general safety and performance standards, their regulatory pathway may involve additional scrutiny or case-by-case review to ensure they meet necessary requirements for patient safety and efficacy.

Elana B.V.’s devices are listed in the FDA’s Unique Device Identification (UDI) database. The UDI system assigns a unique product identifier to each device, allowing for better tracking, monitoring, and transparency in the medical device supply chain. This registration helps healthcare providers, regulators, and manufacturers maintain accurate records of device performance and recall information, ensuring compliance with U.S. medical device regulations.